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Background: Influenza virus undergoes constant antigenic evolution, and therefore influenza vaccines must be
reformulated each year. Time is necessary to produce a vaccine that is antigenically matched to a pandemic strain.
A goal of many research works is to produce universal vaccines that can induce protective immunity to influenza A
viruses of various subtypes. Despite intensive studies, the precise mechanisms of heterosubtypic immunity (HSI)
remain ambiguous.
Method: In this study, mice were vaccinated with recombinant virus vaccine (rL H5), in which the hemagglutinin
(HA) gene of influenza A/H5N1 virus was inserted into the LaSota Newcastle disease virus (NDV) vaccine strain.
Following a challenge with influenza A/H1N1 virus, survival rates and lung index of mice were observed. The
antibodies to influenza virus were detected using hemagglutination inhibition (HI). The lung viral loads, lung
cytokine levels and the percentages of both IFN-γ+CD4+ and IFN-γ+CD8+ T cells in spleen were detected using
real-time RT-PCR, ELISA and flow cytometry respectively.
Results: In comparison with the group of mice given phosphate-buffered saline (PBS), the mice vaccinated with rL
H5 showed reductions in lung index and viral replication in the lungs after a challenge with influenza A/H1N1 virus.
The antibody titer in group 3 (H1N1-H1N1) was significantly higher than that in other groups which only low levels
of antibody were detected. IFN-γ levels increased in both group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1).
And the IFN-γ level of group 2 was significantly higher than that of group 1. The percentages of both IFN-γ+CD4+
and IFN-γ+CD8+ T cells in group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) increased significantly, as
measured by flow cytometry.
Conclusion: After the mice were vaccinated with rL H5, cross-protective immune response was induced, which was
against heterosubtypic influenza A/H1N1 virus. To some extent, cross-protective immune response can be
enhanced by IL-2 as an adjuvant. Cellular immune responses may play an important role in HSI against influenza
virus.
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Influenza A virus (IAV), a member of the Orthomyxoviridae
family, possesses a negative strand RNA genome made
up of eight gene segments. Based on surface proteins
hemagglutinin (HA) and neuraminidase (NA), IAV are
classified 17 HA and 10 NA subtypes [1,2]. Influenza
virus undergoes rapid antigenic evolution by accumula-
tion of mutations and through genetic reassortments of
segments.
IAV causes frequent epidemics, occasional pandemics
and yearly seasonal outbreaks in humans, resulting in
significant morbidity and mortality worldwide [3-5].
Vaccination has been one of the most effective means of
protection against IAV. Due to the constant antigenic
evolution of IAV, influenza vaccines must be reformulated
each year. Although these vaccines are efficacious, they
arrive late and after the peak of a pandemic. Therefore, we
wish to investigate universal vaccines that can induce
protective immunity to IAV of various subtypes [6].
Heterosubtypic immunity (HSI) is the basis of creating
universal influenza vaccines. Evidence supports that
cytokines and T cell responses play crucial roles in HSI
to influenza virus [7,8]. Despite intensive studies, the
precise mechanisms of HSI remain ambiguous.
In this study, mice were vaccinated with recombinant
virus vaccine (rL H5), in which the HA gene of influenza
A/H5N1 virus was inserted into LaSota Newcastle disease
virus (NDV) vaccine strain. The mice were then chal-
lenged with influenza A/H1N1 virus. Furthermore, we
co-administered intraperitoneally recombinant murine
interleukin-2 (rIL-2) with the rL H5 to enhance HSI.
We found that vaccination with rL H5 provided cross-
protection against a lethal challenge with an antigeni-
cally distinct influenza A/H1N1 virus and produced
significant changes in the levels of some cytokines and
the percentages of both IFN-γ+CD4+ and IFN-γ+CD8+
T cells in lung and spleen. We also found that rIL-2 co-
administered with the rL H5 could increase the survival
rate of mice, reduce viral replication in lung and improve
the IFN-γ production.
Results
Clinical outcome and lung index following influenza A/H1N1
virus infection
To determine whether primary immunization with the
rL H5 vaccine can protect against a subsequent infection
with heterosubtypic influenza virus, female 6–8 weeks-
old C57BL/6 mice were immunized with the rL H5
vaccine and infected with influenza A/H1N1 virus with
or without IL-2. The mice were monitored for body
weight loss and survival rates.
The mice in group 2 (rL H5 + IL-2-H1N1) and group
3 (H1N1-H1N1) all survived after infection. The survival
rate of mice in group 1 (rL H5-H1N1) was 58% at day14 post-infection (p.i.). The mice in group 4 (PBS-H1N1)
were all dead at day 7 p.i. (Figure 1A). The survival rate of
group 2 (rL H5 + IL-2-H1N1) was higher than the survival
rate of group 1 (rL H5-H1N1). Mice vaccinated with NDV
were all dead at day 7 p.i. (data not shown). These results
demonstrated that there was cross-protection between the
H5 and H1 subtypes of influenza virus and that IL-2 as
adjuvant could increase the survival rate of mice. NDV
and IAV had not cross-protection.
The low lung index correlated well with strong pro-
tection during IAV infection. The lung index of group 1
(rL H5-H1N1) was 0.87%, group 2 (rL H5 + IL-2-H1N1)
was 0.74%, and group 4 (PBS-H1N1) was 1.51% at day 7 p.i..
The lung indexes of group 1 and group 2 were lower than
in group 4 at day 7 p.i. (P < 0.05) (Figure 1B). These data
showed that rL H5 vaccine could prevent the mice from
weights loss and inflammation of lung when they were
challenged with influenza A/H1N1 virus.
Viral load in the lungs of mice
The viral loads in the lungs of the mice were assessed
using a real-time RT-PCR method at day 5 p.i. (Figure 1C).
The lung viral loads of group 1 (rL H5-H1N1) and group
2 (rL H5 + IL-2-H1N1) were significantly lower than
group 4 (P < 0.05). The lung viral loads of group 2 were
lower than group 1 (P < 0.05). These data demonstrated
that rL H5 induced cross-protection against A/H1N1 virus
infection which may be enhanced by IL-2.
Hemagglutination inhibition antibody responses
To determine whether the antibody had the protective
effect against influenza A/H1N1 virus, we detected the
levels of antibodies against influenza A/H1N1 virus in
sera of mice by Hemagglutination inhibition (HI) assay
(Table 1). The antibody titer in group 3 (H1N1-H1N1)
was 640 at day 14 p.i.. It was significantly higher compared
with the other groups that only low levels of antibody
were detected. These data demonstrated that the levels of
antibody might play a critical role in homologous influ-
enza virus infection, but showed a negative correlation
between HSI and antibody levels.
Cytokine expression in the lungs of mice
Lung suspensions were analyzed for Th1-type and Th2-
type cytokine levels using ELISA. High levels of IFN-γ
were detected in group 1 (rL H5-H1N1) and group 2 (rL
H5 + IL-2-H1N1). The IFN-γ and IL-10 levels of group 1
(rL H5-H1N1) were significantly higher than in group 3
(H1N1-H1N1) at day 7 p.i. (P < 0.05). The IFN-γ level of
group 2 (rL H5 + IL-2-H1N1) was significantly higher
than in group 1 (rL H5-H1N1) at day 7 p.i. (P < 0.05).
The IFN-γ and IL-10 levels of group 1 and group 2 were
significantly elevated after infection as compared to day
0 (P < 0.05) (Figure 2A and D).




Antibody titers against H1 virus (HI)
Day 7 Day 14
rLH5-H1N1 <40 <40




A titer of <40 represents the lower limit of detection.
n.d. = not done. Animals did not survive until these time points.
Figure 1 Clinical outcome and lung index following influenza A/H1N1 virus infection. (A) Survival rate of mice after infection with
influenza A/H1N1 virus, which was significantly higher after day 6 for the rL H5-primed mice. n = 12/group. (B) The lung index of mice after
infection with influenza A/H1N1 virus (*, as compare with group 4 [PBS-H1N1], P < 0.05). n = 3/group. (C) Lung viral loads on day 5 p.i. with
influenza A/H1N1 virus (a, as compare with group 1 [rL H5-H1N1], P < 0.05; b, as compare with group 3 [H1N1- H1N1], P < 0.05; c, as compare
with group 4 [PBS-H1N1], P < 0.05). n = 3/group.
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in all groups of mice (Figure 2B and C). These results sug-
gested that IFN-γ and IL-10 may play roles in HSI. IL-2
co-administrated with rL H5 vaccine could improve the
IFN-γ production.
The percentages of both IFN-γ+CD4+ T cells and IFN-γ+CD8+
T cells in spleen
To investigate the roles of Th1 lymphocytes and cyto-
toxic T-lymphocytes (CTL) in HSI to influenza virus,
the percentages of IFN-γ+CD4+ and IFN-γ+CD8+ T cells
in spleen were assessed using flow cytometry. The
percentages of IFN-γ+CD4+ and IFN-γ+CD8+ T cells
had not significant change at day 5 p.i.. The percentages
of IFN-γ+CD4+ T cells of mice group 1 (rL H5-H1N1)
and group 2 (rL H5 + IL-2-H1N1) were significantly
higher than in group 3 (H1N1-H1N1) and group 4
(PBS-H1N1) at day 7 p.i. (P < 0.05) (Figure 3A). The
percentages of IFN-γ+CD8+ T cells of mice group 1 (rL
H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) were
significantly higher than in group 4 (PBS-H1N1) at day
7 p.i. (P < 0.05) (Figure 3B). These data demonstratedthat rL H5 vaccine induced high frequencies of Th1
cells and CTL.
Discussion
HSI to influenza virus can be successfully induced by
live or inactivated whole influenza viruses or DNA vac-
cines in different kinds of animals [9-13]. In our re-
search, we primed mice with NDV-based recombinant
virus vaccine expressing HA gene of influenza A/H5N1
Figure 2 Induction of cytokines by influenza A/H1N1 virus. The levels of IFN-γ (A), IL-2 (B), IL-4 (C) and IL-10 (D) in the lung suspensions
were detected by ELISA assay (a, as compare with group 1 (rL H5-H1N1), P < 0.05; b, as compare with group 3 (H1N1- H1N1), P < 0.05; c, as
compare with 0day of the same group, P < 0.05). n = 3/group.
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A/H1N1 virus infection from severe disease, death and
viral replication in the lungs. Ge et al. [14] demonstrated
that the NDV portion of rLH5 vaccine protected mice
from NDV infection and could not provide protection
from influenza A/H5N1 virus infection. We also found
that the NDV portion of vaccine does not elicit cross-
protection against influenza A/H1N1 virus infection
(data not shown). Therefore, the protective efficacy of
HSI in our experiments was induced by gene of influ-
enza virus in rLH5 vaccine.
Current vaccines generate neutralizing antibodies di-
rected against viral HA and NA surface glycoproteins of
homologous influenza viruses [15]. According to Genbank
(ADG59526.1 and AAC53844.1), the amino acid hom-
ology of HA of A/Font Monmouth/1/1947 (H1N1) and
A/Bar-headed goose/Qinghai/3/2005 (H5N1) was 62%. In
this study, antibodies against influenza A/H1N1 virus in
sera were determined by HI assay after infection. The
results showed a strong antibody response to influenza
A/H1N1 virus in group 3 (H1N1-H1N1) that played a
critical role in immune responses to homologous influenza
virus infection. We observed low or undetectable levels of
antibodies to influenza A/H1N1 virus in the other groups.
It indicated a negative correlation between HSI and anti-
body levels.
We found that the IFN-γ and IL-10 levels in the lung
samples from group 1 (rL H5-H1N1) and group 2 (rL
H5 + IL-2-H1N1) were significantly high after infection
in comparison to the other groups . IFN-γ, a Th1 cytokine,
can enhance the phagocytic function of macrophages andthe cytotoxic effect of NK cells. CTL, which can lyse target
cells and prevent spread of influenza virus in vivo, can
be activated by IFN-γ [8,16-18]. IL-10 is an anti-
inflammatory cytokine. Although IL-10 is a Th2 cytokine,
it can inhibit the generation of inflammatory mediators
and prevent imbalances of the inflammatory reaction [19].
High levels of IFN-γ and IL-10 can help clear influenza
virus, combat excessive inflammation and promote
recovery.
T-cell-mediated immune responses are an important
factor in HSI to influenza virus. IFN-γ+CD4+ T cells are
Th1 cells and IFN-γ+CD8+ T cells are effector CTL that
are critical features of an adaptive immune system [20-22].
In this study, high frequencies of activated IFN-γ+CD4+
and IFN-γ+CD8+ T cells in mice of group 1 (rL H5-H1N1)
and group 2 (rL H5 + IL-2-H1N1) were elicited by influ-
enza A/H1N1 virus challenge. It indicated that T-cell-
mediated immunity might play an important role in
cross-protection between different subtypes of influenza
virus.
Vaccines that broadly induce cross-reactive T cell
responses are usually directed against conserved viral
epitopes of internal proteins, such as NP proteins
[23,24]. De Groot et al. [25] reported that the HA also
possesses cross-conserved T-cell epitopes [26-28]. We
had found that there was no correlation between the
levels of antibody and HSI against influenza virus. And
our results showed that the levels of IFN-γ and the per-
centages of both IFN-γ+CD4+ and IFN-γ+CD8+ T cells in
group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1)
increased significantly after infection. We speculate that
Figure 3 The percentages of IFN-γ+CD4+ T cells and IFN-γ+CD8+ T cells in spleen. The percentages of IFN-γ+CD4+ T cells (A) and IFN-γ+CD8+
T cells (B) were assayed using anti-CD3, anti-CD4, anti-CD8b and anti-IFN-γ mAb by flow cytometry. The frequencies of CD3+CD4+ and CD3+CD8+
splenocytes were determined by intracellular IFN-γ staining. (a, as compare with group 4 (PBS-H1N1), P < 0.05; b, as compare with group 3
(H1N1- H1N1), P < 0.05.). n = 3/group.
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A/H1N1 viruses in mice may be due to cross-conserved
T-cell epitope sequences in HA.
Some researchers have used various adjuvants such as
IL-2, IL-12, GM-CSF or the heat-labile enterotoxin from
enterotoxigenic Escherichia coli to improve immune
responses [29,30]. In this study, we selected rIL-2 as an
adjuvant to enhance HSI. We found that the mice in the
group that co-administered with IL-2 had higher survival
rates, lower viral loads and greater amount of IFN-γ pro-
duction. Henke et al. [31] reported that IL-2 increased the
efficacy of DNA immunization to prevent influenza virus
infections, IL-2 as an adjuvant for vaccination can stimu-
late the proliferation and activation of T cells, NK cells
and macrophage. It can also enhance cellular immunity
[32]. Further studies will be done to clarify the mechanism
that IL-2, as an adjuvant, enhance HSI.In summary, rLH5 vaccine induced cross-protective im-
mune response against heterosubtypic influenza A/H1N1
virus infection in mice, and this cross-protection was
improved with IL-2 as an adjuvant. T cell immunity may
play an important role in HSI against influenza virus.
Further studies will be necessary to determine the most
effective cross-conserved T-cell epitope to HSI and the
precise mechanism of HSI.Materials and Methods
Mice
Healthy female C57BL/6 mice 6–8 weeks of age were
obtained from the Laboratory Animal Center of China
Medical University. Mice were bred and/or housed
under specific pathogen-free (SPF) conditions until the
day of sacrifice. The Institutional Ethics Committee for
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iments and procedures.
Influenza virus and vaccine
Influenza viruses A/Font Monmouth/1/1947 (A/FM/1/
47) (H1N1) were propagated in the allantoic cavity of 10
day-old embryonated SPF chicken eggs at 34°C, and
allantoic fluid was harvested after 2–3 days. Fifty percent
egg infectious dose (EID50) titers were determined by
serial titration of viruses in eggs and calculated by the
method of Reed and Muench [8].
rL H5 vaccine was purchased from Harbin Veterinary
Research Institute. HA open reading frame from A/Bar-
headed goose/Qinghai/3/2005 (H5N1) were inserted into
the intergenic region between the P and M genes of the
LaSota NDV vaccine strain.
Immunization and challenge of mice
Mice were anesthetized by intraperitoneal injection with
tribromoethanol (Avertin; 250 to 300 μl per mouse) [33].
Mice were intranasally inoculated with 106.0 EID50 of rL
H5 vaccine in a volume of 50 μl. Three weeks later,
the mice were re-immunized in the same manner
with the same amount of the vaccine. Two weeks
after re-immunization, mice were intranasally infected
with 104.8 EID50 of influenza A/H1N1 virus in a volume
of 50 μl. Mice were divided into six groups (Table 2).
Group 1 (rL H5-H1N1): Mice were primed with rL H5
vaccine and infected with influenza A/H1N1 virus as de-
scribed above; Group 2 (rL H5 + IL-2-H1N1): Mice were
primed with rL H5 vaccine and 160 U of rIL-2 in a volume
of 100 μl PBS was co-administered intraperitoneally 3 days
after the primary and secondary immunization. Mice were
challenged with influenza A/H1N1 virus as in group 1;
Group 3 (H1N1-H1N1): Mice were intranasally inoculated
with 102.8 EID50 of influenza A/H1N1 virus in a volume of










+ - - +
Group 2
(rLH5 + IL-2-H1N1)
+ + - +
Group 3
(H1N1-H1N1)
- - + +
Group 4
(PBS-H1N1)
- - - +
Group 5
(IL-2-H1N1)
- + - +
Group 6 - - - -in group 1 [20]; Group 4 (PBS-H1N1): Mice were given
PBS in a volume of 50 μl and were challenged with influ-
enza A/H1N1 virus as in group 1; Group 5 (IL-2-H1N1):
Mice were injected intraperitoneally with rIL-2 in the
same manner as group 2 and were challenged with in-
fluenza A/H1N1 virus as in group 1; Group 6: Negative
control group.
Mice (n = 12/group) were monitored daily for body
weight and survival rates after infection. At day 0, 5 and
7 p.i., mice were euthanized and their lungs and spleen
were resected.
Lung index assays
Three mice from each group were euthanized and their
lungs were weighed. Lung index is expressed as percent-
age of weight, according to the formula: lung weight/
body weight × 100%.
HI assay
Mice (n = 3) from each group were bled via the orbital
sinus vein and the sera were collected at day 7 and 14 p.i..
HI assay was performed as previously described [34,35].
Cytokine assays
Intact lungs of mice (n = 3) from each group were pre-
pared to assess cytokine levels at days 0 and 7 p.i..
Whole lungs were homogenized using a conventional
method [36]. Homogenates were centrifuged at 300 g
for 10 min., and supernatants were collected. The
amounts of interferon-γ (IFN-γ), IL-2, IL-4 and IL-10 in
lung suspensions were measured using ELISA as described
previously [34].
Flow-cytometric analysis
The virus-specific IFN-γ+CD4+ and IFN-γ+CD8+ T cells
were analyzed using flow cytometry. Splenocytes of mice
(n = 3) from each group were collected at day 0, 5 and 7 p.i..
Single-cell suspensions were prepared as previously de-
scribed [9]. 1 × 106 splenocytes were plated to a 96-well
flat-bottom plate and stimulated with infectious influenza
A/H1N1 virus at an MOI of 0.1 in 200 μl volume for 21 h
[27]. Bredfeldin A (BD GolgiPlug) was added at a final
concentration of 1 μg/ml for the last 5 h of incubation to
block protein transport. Cells were stained intracellularly
for fluorescein isothiocyanate (FITC)-anti-INF-γ after sur-
face staining for Peridinin-Chlorophyll-Protein Complex
(PerCP)-anti-CD3, phycoerythrin (PE)-anti-CD4 or PE-
anti-CD8b (Becton Dickinson). Stained cells were quanti-
fied using a FACS Calibur (BD Biosciences) and analysed
using the FlowJo software (Treestar).
Virus quantification assays
Lung suspensions of mice (n = 3) from each group were
prepared at day 5 p.i.. Influenza virus in the lung
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[37]. Total virus RNA was prepared using the RNAiso
Plus (TaKaRa) following the manufacturer’s instructions.
The primer sequences used for RT-PCR and quantitative
real time PCR of the viral NP gene were 5′-CTGAGAA
GCAGGTACTGGGC-3′ (sense) and 5′-CTGCATTGTC
TCCGAAGAAAT-3′ (antisense).
Real-time RT-PCR was performed using the SYBR®
PrimeScript® RT-PCR kit (Perfect Real Time, TaKaRa). A
20 μl reaction volume was prepared according to the
manufacturer’s instructions. Cycling conditions for real-
time RT-PCR were as follows: 37°C for 15 min, 85°C for
5 s, 95°C for 30 s followed by 40 cycles of 95°C for 5 s,
55°C for 34 s. Real-time RT-PCR was conducted using
the ABI 7500 and the data were analyzed using ABI
software.
Conventional RT-PCR was carried out using the
extracted RNA and primers as described above. The
concentration of the RT-PCR product was determined
by measuring the OD at 260 nm using a spectrophotometer
(Eppendorf) [38]. Serial 10-fold dilutions of the product
DNA with EASY dilution (TaKaRa) were used in real-time
PCR and the standard curve generated from the amplifica-
tion plot.
Statistical analysis
Statistical analyses were carried out using the SPSS 17.0
software. The differences between values were evaluated
through a one-way analysis of variance (ANOVA) followed
by pair-wise comparison with the Student-Newman-Keuls
test. P < 0.05 was considered statistically significant and all
values are expressed as means ± SEM. All experiments
were performed at least three times.
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